BiotechTube

Eylea + ALT-L9

Phase 1Completed
0 watching 0 views this week๐Ÿ’ค Quiet
33
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neovascular Age-related Macular Degeneration

Conditions

Neovascular Age-related Macular Degeneration

Trial Timeline

Feb 5, 2020 โ†’ Dec 22, 2020

NCT ID
NCT04058535

About Eylea + ALT-L9

Eylea + ALT-L9 is a phase 1 stage product being developed by Alteogen for Neovascular Age-related Macular Degeneration. The current trial status is completed. This product is registered under clinical trial identifier NCT04058535. Target conditions include Neovascular Age-related Macular Degeneration.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT04058535Phase 1Completed

Competing Products

20 competing products in Neovascular Age-related Macular Degeneration

See all competitors
ProductCompanyStageHype Score
CLS-AX + Anti-VEGFClearside BiomedicalPhase 1/2
33
CLS-AX + AfliberceptClearside BiomedicalPhase 2
44
UBX1325 injection 50 ฮผL + EYLEAยฎ (aflibercept) Injection 2 mg (0.05mL)Unity BiotechnologyPhase 2
44
DS-7080a + RanibizumabDaiichi SankyoPhase 1
33
Avacincaptad PegolAstellas PharmaPhase 1
33
Avacincaptad Pegol + Avastin + Lucentis + EyleaAstellas PharmaPhase 2
52
Avacincaptad Pegol + LucentisAstellas PharmaPhase 2
52
KHK4951 + Aflibercept InjectionKyowa KirinPhase 2
52
Surabgene Lomparvovec (ABBV-RGX-314) + Ranibizumab ControlAbbViePhase 3
77
Ranibizumab + Local Steroid + Topical SteroidAbbViePhase 2
52
LucentisNovartisPre-clinical
23
ranibizumabNovartisPhase 3
77
BrolucizumabNovartisPre-clinical
23
ranibizumabNovartisApproved
85
brolucizumab + ranibizumab + afliberceptNovartisPre-clinical
23
BeovuNovartisPre-clinical
23
RanibizumabNovartisPhase 3
77
RanibizumabNovartisApproved
85
Intraviteal Ranibizumab 0.5mgNovartisApproved
85
RanibizumabNovartisApproved
85

Other Products from Alteogen

ALT02 + EU-licensed Herceptin + US-licensed HerceptinPhase 1
33
ALT-BB4 + 0.9%NaClPhase 1
33
ALT-P7 (HM2-MMAE)Phase 1
33